BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 2905252)

  • 21. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity.
    Netzer P; Brabetz-Höfliger A; Bründler R; Flogerzi B; Hüsler J; Halter F
    Aliment Pharmacol Ther; 1998 Apr; 12(4):337-42. PubMed ID: 9690722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
    Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
    Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of roxatidine acetate and ranitidine in gastric ulcer healing.
    Judmaier G
    Drugs; 1988; 35 Suppl 3():120-6. PubMed ID: 2905240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nocturnal intragastric acidity after over-the-counter doses of famotidine, ranitidine or placebo.
    Grimley CE; Cottrell J; Mann SG; Stauffer L; Nwokolo CU
    Aliment Pharmacol Ther; 1997 Oct; 11(5):881-5. PubMed ID: 9354196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.
    Nwokolo CU; Smith JT; Sawyerr AM; Pounder RE
    Gut; 1991 Dec; 32(12):1455-60. PubMed ID: 1685465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of low doses of ranitidine on intragastric acidity in healthy men.
    Wyeth JW; Pounder RE; Sercombe JC; Snell CC
    Aliment Pharmacol Ther; 1998 Mar; 12(3):255-61. PubMed ID: 9570260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency.
    Gladziwa U; Wagner S; Sieberth HG; Klotz U
    Br J Clin Pharmacol; 1995 Feb; 39(2):161-7. PubMed ID: 7742154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of oral famotidine on 24-hour intragastric acidity.
    Santana IA; Lanzon-Miller S; Pounder RE
    Postgrad Med J; 1986; 62 Suppl 2():39-42. PubMed ID: 2890150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Plasma pharmacokinetics of roxatidine in the healthy man: correlation with gastric antisecretory effect].
    Chen WW; Kolsky H; Lewin MJ; Bonfils S
    Gastroenterol Clin Biol; 1990; 14(4):342-6. PubMed ID: 1972124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine.
    Nwokolo CU; Smith JT; Gavey C; Sawyerr A; Pounder RE
    Aliment Pharmacol Ther; 1990; 4 Suppl 1():29-45. PubMed ID: 1983345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.
    Peghini PL; Katz PO; Castell DO
    Gastroenterology; 1998 Dec; 115(6):1335-9. PubMed ID: 9834259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of GR122311X, a bismuth compound with H2-antagonist activity, on 24-hour intragastric acidity.
    Prewett EJ; Nwokolo CU; Hudson M; Sawyerr AM; Fraser A; Pounder RE
    Aliment Pharmacol Ther; 1991 Oct; 5(5):481-90. PubMed ID: 1686562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
    Abdul-Hussein M; Freeman J; Castell D
    Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of food-stimulated acid secretion (intragastric titration) by roxatidine acetate. Dose-response study.
    Bonfils S; Chen WW; Vatier J
    Scand J Gastroenterol Suppl; 1988; 146():135-41. PubMed ID: 2906457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the animal pharmacology of roxatidine acetate.
    Scholtholt J; Bickel M; Herling AW
    Drugs; 1988; 35 Suppl 3():30-40. PubMed ID: 2905247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75 mg: a comparative study with cimetidine and placebo.
    Grimley CE; Constantinides S; Snell CC; Mills JG; Nwokolo CU
    Aliment Pharmacol Ther; 1997 Oct; 11(5):875-9. PubMed ID: 9354195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of 300 mg ranitidine at night, twice daily and four times daily on intragastric acidity in normal subjects.
    Primrose JN; Rogers MJ; Holmfield JH
    Aliment Pharmacol Ther; 1993 Jun; 7(3):287-91. PubMed ID: 8364134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roxatidine versus ranitidine in the treatment of duodenal ulcers: a randomized double-blind controlled multicentre study in Singapore.
    Fock KM; Kang JY; Ng HS; Ng TM; Gwee KA; Lim CC
    J Gastroenterol Hepatol; 1995; 10(4):379-82. PubMed ID: 8527701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of 15 days of dosing with placebo, sufotidine 600 mg nocte or sufotidine 600 mg twice daily upon 24-hour intragastric acidity and 24-hour plasma gastrin.
    Rogers MJ; Holmfield JH; Primrose JN; Johnston D
    Aliment Pharmacol Ther; 1990; 4 Suppl 1():65-74. PubMed ID: 1983347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single dose treatment with H2 receptor antagonists: is bedtime administration too late?
    Merki H; Witzel L; Harre K; Scheurle E; Neumann J; Röhmel J
    Gut; 1987 Apr; 28(4):451-4. PubMed ID: 3583073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.